Format

Send to

Choose Destination
Infect Immun. 2014 Nov;82(11):4707-17. doi: 10.1128/IAI.02061-14. Epub 2014 Aug 25.

Use of immunodampening to overcome diversity in the malarial vaccine candidate apical membrane antigen 1.

Author information

1
Department of Biochemistry, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Australia.
2
Centre for Biomedical Research, Burnet Institute, Melbourne, Australia.
3
Department of Structural Vaccinology, Malaria Vaccine Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
4
Department of Biochemistry, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Australia m.foley@latrobe.edu.au.

Abstract

Apical membrane antigen 1 (AMA1) is a leading malarial vaccine candidate; however, its polymorphic nature may limit its success in the field. This study aimed to circumvent AMA1 diversity by dampening the antibody response to the highly polymorphic loop Id, previously identified as a major target of strain-specific, invasion-inhibitory antibodies. To achieve this, five polymorphic residues within this loop were mutated to alanine, glycine, or serine in AMA1 of the 3D7 and FVO Plasmodium falciparum strains. Initially, the corresponding antigens were displayed on the surface of bacteriophage, where the alanine and serine but not glycine mutants folded correctly. The alanine and serine AMA1 mutants were expressed in Escherichia coli, refolded in vitro, and used to immunize rabbits. Serological analyses indicated that immunization with a single mutated form of 3D7 AMA1 was sufficient to increase the cross-reactive antibody response. Targeting the corresponding residues in an FVO backbone did not achieve this outcome. The inclusion of at least one engineered form of AMA1 in a biallelic formulation resulted in an antibody response with broader reactivity against different AMA1 alleles than combining the wild-type forms of 3D7 and FVO AMA1 alleles. For one combination, this extended to an enhanced relative growth inhibition of a heterologous parasite line, although this was at the cost of reduced overall inhibitory activity. These results suggest that targeted mutagenesis of AMA1 is a promising strategy for overcoming antigenic diversity in AMA1 and reducing the number of variants required to induce an antibody response that protects against a broad range of Plasmodium falciparum AMA1 genotypes. However, optimization of the immunization regime and mutation strategy will be required for this potential to be realized.

PMID:
25156737
PMCID:
PMC4249334
DOI:
10.1128/IAI.02061-14
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center